SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
Scholar Rock still expects a decision on its application by the September 30 target date. In September 2025,…
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing
The company said it has, in accordance with FDA guidance, removed Catalent Indiana—a fill-finish plant now owned by…
Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?
Two healthcare players, Scholar Rock Holding Corporation (NASDAQ:SRRK) and Novo Nordisk A/S (NYSE:NVO), find their near-term narratives intertwined…
Novo’s Catalent plant ditched in FDA refiling of SMA drug
Scholar Rock has shed Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for…